Am J Perinatol 2019; 36(11): 1127-1135
DOI: 10.1055/s-0038-1676489
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Associations between Maternal Exposure to Bisphenol A or Triclosan and Gestational Hypertension and Preeclampsia: The MIREC Study

Louopou Rosalie Camara
1   Social and Preventive Medicine Department, Public Health School, Université de Montréal, Quebec, Canada
2   Research Center, CHU Sainte-Justine, Mother and Child University Hospital Center, Montreal, Quebec, Canada
,
Tye Elaine Arbuckle
3   Population Studies Division, Environmental Health Science and Research Bureau, Healthy Environments and Consumer Safety Branch, Health Canada, Ottawa, Ontario, Canada
,
Helen Trottier
1   Social and Preventive Medicine Department, Public Health School, Université de Montréal, Quebec, Canada
2   Research Center, CHU Sainte-Justine, Mother and Child University Hospital Center, Montreal, Quebec, Canada
,
William Donald Fraser
2   Research Center, CHU Sainte-Justine, Mother and Child University Hospital Center, Montreal, Quebec, Canada
4   CHU Sherbrooke Research Center, Department of Obstetrics and Gynecology, Université de Sherbrooke, Sherbrooke, Quebec, Canada
› Author Affiliations
Funding The MIREC Study was funded by Health Canada's Chemicals Management Plan, the Canadian Institute of Health Research (CIHR; grant MOP-81285), and the Ontario Ministry of the Environment. Author L.R.C. received a PhD scholarship from MIREC and QTNPR (Quebec Perinatal Research Training Network). Author H.T. holds a salary award (chercheur-boursier) from the Fonds de la recherche du Québec en santé (FRQ-S) and from CIHR (New investigator salary award). Author W.D.F. holds a Tier 1 CIHR Canada Research Chair.
Further Information

Publication History

22 June 2018

25 October 2018

Publication Date:
14 December 2018 (online)

Abstract

Background Little is known about the association between bisphenol A (BPA) or triclosan (TCS) exposure and hypertension in pregnancy.

Objective To investigate potential associations between maternal urinary concentrations of BPA or TCS and gestational hypertension (GH) and preeclampsia.

Study Design Among 1,909 pregnant women participating in the maternal-infant research on environmental chemicals (MIREC) study, urinary concentrations of BPA and TCS were measured in the first trimester by liquid chromatography-tandem mass spectrometry using isotope dilution. Blood pressure was measured during each trimester. Multinomial regression was performed to estimate the adjusted odds ratio (aOR) and 95% confidence intervals (CI) for the associations between these phenols and GH and preeclampsia.

Results BPA and TCS were not associated with GH or preeclampsia. However, in multiparous women, BPA (0.50–1.30 µg/L) was associated with decreased risk of GH (aOR =0.45; 95%CI: 0.21–0.98) while among nulliparous women, TCS was associated with an increased risk of GH (3.60–32.60 µg/L; aOR = 2.58; 95% CI: 1.09–6.13 and > 32.60 µg/L: aOR = 2.74; 95% CI: 1.15–6.51).

Conclusion BPA and TCS urinary concentrations were not associated with GH or preeclampsia; however, our results suggest an association between TCS and GH in nulliparous women. Additional studies are required to confirm our results.

Supplementary Material

 
  • References

  • 1 Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension 2009; 53 (06) 944-951
  • 2 Nakimuli A, Nakubulwa S, Kakaire O. , et al. The burden of maternal morbidity and mortality attributable to hypertensive disorders in pregnancy: a prospective cohort study from Uganda. BMC Pregnancy Childbirth 2016; 16: 205
  • 3 Riaz S, Habib S, Jabeen A. Frequency of maternal mortality and morbidity in pregnancy-induced hypertension. J Ayub Med Coll Abbottabad 2011; 23 (04) 61-63
  • 4 Berhan Y, Endeshaw G. Maternal mortality predictors in women with hypertensive disorders of pregnancy: a retrospective cohort study. Ethiop J Health Sci 2015; 25 (01) 89-98
  • 5 Lo JO, Mission JF, Caughey AB. Hypertensive disease of pregnancy and maternal mortality. Curr Opin Obstet Gynecol 2013; 25 (02) 124-132
  • 6 Moodley J. Maternal deaths associated with hypertensive disorders of pregnancy: a population-based study. Hypertens Pregnancy 2004; 23 (03) 247-256
  • 7 Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33 (03) 130-137
  • 8 Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. ; Canadian Hypertensive Disorders of Pregnancy Working Group Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 2014; 36 (05) 416-441
  • 9 Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens 2008; 21 (05) 521-526
  • 10 Public Health Agency of Canada. Maternal hypertension in Canada. October 2014. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/maternal-hypertension-canada.html . Accessed August 16, 2017
  • 11 Ali SM, Khalil RA. Genetic, immune and vasoactive factors in the vascular dysfunction associated with hypertension in pregnancy. Expert Opin Ther Targets 2015; 19 (11) 1495-1515
  • 12 Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011; 123 (24) 2856-2869
  • 13 Robillard PY, Dekker G, Chaouat G. Sixth international workshop on reproductive immunology, immunological tolerance and immunology of preeclampsia. Preface. J Reprod Immunol 2009; 82 (02) 95
  • 14 Robillard PY, Dekker G, Chaouat G, Hulsey TC, Saftlas A. Epidemiological studies on primipaternity and immunology in preeclampsia--a statement after twelve years of workshops. J Reprod Immunol 2011; 89 (02) 104-117
  • 15 Cantonwine DE, Meeker JD, Ferguson KK, Mukherjee B, Hauser R, McElrath TF. Urinary concentrations of bisphenol A and phthalate metabolites measured during pregnancy and risk of preeclampsia. Environ Health Perspect 2016; 124 (10) 1651-1655
  • 16 Pregnancy hypertension. In: Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY, eds. Williams Obstetrics. 23rd edition. New York, NY. McGraw-Hill; 2010:706–756
  • 17 Kobashi G. Genetic and environmental factors associated with the development of hypertension in pregnancy. J Epidemiol 2006; 16 (01) 1-8
  • 18 FDA (U.S. Food and Drug Administration). 5 things to know about triclosan. 2016a. Available at: https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm205999.htm . Accessed July 14, 2017
  • 19 FDA (U.S. Food and Drug Administration). Bisphenol A (BPA): use in food contact application. 2016b. Available at: https://www.fda.gov/newsevents/publichealthfocus/ucm064437.htm . Accessed July 14, 2017
  • 20 GOC (Government of Canada). Triclosan. 2016. Available at: https://www.canada.ca/en/health-canada/services/chemicals-product-safety/triclosan.html . Accessed July 14, 2017
  • 21 GOC (Government of Canada). Bisphenol A in batch 2 of the challenge. 2017. Available at: https://www.canada.ca/en/health-canada/services/chemical-substances/challenge/batch-2/bisphenol-a.html . Accessed July 14, 2017
  • 22 Völkel W, Colnot T, Csanády GA, Filser JG, Dekant W. Metabolism and kinetics of bisphenol a in humans at low doses following oral administration. Chem Res Toxicol 2002; 15 (10) 1281-1287
  • 23 Kang JH, Kondo F, Katayama Y. Human exposure to bisphenol A. Toxicology 2006; 226 (2, 3): 79-89
  • 24 Vandenberg LN, Hauser R, Marcus M, Olea N, Welshons WV. Human exposure to bisphenol A (BPA). Reprod Toxicol 2007; 24 (02) 139-177
  • 25 von Goetz N, Pirow R, Hart A. , et al. Including non-dietary sources into an exposure assessment of the European Food Safety Authority: The challenge of multi-sector chemicals such as Bisphenol A. Regul Toxicol Pharmacol 2017; 85: 70-78
  • 26 Bae S, Hong YC. Exposure to bisphenol A from drinking canned beverages increases blood pressure: randomized crossover trial. Hypertension 2015; 65 (02) 313-319
  • 27 Shiue I. Higher urinary heavy metal, arsenic, and phthalate concentrations in people with high blood pressure: US NHANES, 2009-2010. Blood Press 2014; 23 (06) 363-369
  • 28 Wang T, Xu M, Xu Y. , et al. Association of bisphenol A exposure with hypertension and early macrovascular diseases in Chinese adults: a cross-sectional study. Medicine (Baltimore) 2015; 94 (43) e1814
  • 29 Leclerc F, Dubois MF, Aris A. Maternal, placental and fetal exposure to bisphenol A in women with and without preeclampsia. Hypertens Pregnancy 2014; 33 (03) 341-348
  • 30 Asimakopoulos AG, Xue J, De Carvalho BP. , et al. Urinary biomarkers of exposure to 57 xenobiotics and its association with oxidative stress in a population in Jeddah, Saudi Arabia. Environ Res 2016; 150: 573-581
  • 31 Rezg R, El-Fazaa S, Gharbi N, Mornagui B. Bisphenol A and human chronic diseases: current evidences, possible mechanisms, and future perspectives. Environ Int 2014; 64: 83-90
  • 32 Aboul Ezz HS, Khadrawy YA, Mourad IM. The effect of bisphenol A on some oxidative stress parameters and acetylcholinesterase activity in the heart of male albino rats. Cytotechnology 2015; 67 (01) 145-155
  • 33 Byun JA, Heo Y, Kim YO, Pyo MY. Bisphenol A-induced downregulation of murine macrophage activities in vitro and ex vivo. Environ Toxicol Pharmacol 2005; 19 (01) 19-24
  • 34 Cindrova-Davies T. Gabor Than Award Lecture 2008: pre-eclampsia–from placental oxidative stress to maternal endothelial dysfunction. Placenta 2009; 30 (Suppl A): S55-S65
  • 35 Myatt L, Cui X. Oxidative stress in the placenta. Histochem Cell Biol 2004; 122 (04) 369-382
  • 36 Reslan OM, Khalil RA. Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia. Cardiovasc Hematol Agents Med Chem 2010; 8 (04) 204-226
  • 37 Khalil RA, Granger JP. Vascular mechanisms of increased arterial pressure in preeclampsia: lessons from animal models. Am J Physiol Regul Integr Comp Physiol 2002; 283 (01) R29-R45
  • 38 Bergstrom KG. Update on antibacterial soaps: the FDA takes a second look at triclosans. J Drugs Dermatol 2014; 13 (04) 501-503
  • 39 ECCC (Environment and Climate Change Canada). Canadian environmental protection act, 1999 draft federal environmental quality guidelines, triclosan. 2017. Available at: http://www.ec.gc.ca/ese-ees/default.asp?lang=En&n=F6CF7AA4-1 . Accessed July 14, 2017
  • 40 Cullinan MP, Palmer JE, Faddy MJ. , et al. The influence of triclosan on biomarkers of cardiovascular risk in patients in the cardiovascular and periodontal study (caps): a randomized controlled trial. J Periodontol 2015; 86 (07) 847-855
  • 41 Shiue I. Higher urinary heavy metal, phthalate, and arsenic but not parabens concentrations in people with high blood pressure, U.S. NHANES, 2011-2012. Int J Environ Res Public Health 2014; 11 (06) 5989-5999
  • 42 Shiue I, Hristova K. Higher urinary heavy metal, phthalate and arsenic concentrations accounted for 3–19% of the population attributable risk for high blood pressure: US NHANES, 2009-2012. Hypertens Res 2014; 37 (12) 1075-1081
  • 43 Barros SP, Wirojchanasak S, Barrow DA, Panagakos FS, Devizio W, Offenbacher S. Triclosan inhibition of acute and chronic inflammatory gene pathways. J Clin Periodontol 2010; 37 (05) 412-418
  • 44 Wallet MA, Calderon Nl, Alonso TR. , et al. Triclosan alters antimicrobial and inflammatory responses of epithelial cells. Oral Dis 2013; 19 (03) 296-302
  • 45 Watkins DJ, Ferguson KK, Anzalota Del Toro LV, Alshawabkeh AN, Cordero JF, Meeker JD. Associations between urinary phenol and paraben concentrations and markers of oxidative stress and inflammation among pregnant women in Puerto Rico. Int J Hyg Environ Health 2015; 218 (02) 212-219
  • 46 Lockwood CJ, Yen CF, Basar M. , et al. Preeclampsia-related inflammatory cytokines regulate interleukin-6 expression in human decidual cells. Am J Pathol 2008; 172 (06) 1571-1579
  • 47 Arbuckle TE, Fraser WD, Fisher M. , et al. Cohort profile: the maternal-infant research on environmental chemicals research platform. Paediatr Perinat Epidemiol 2013; 27 (04) 415-425
  • 48 Provencher G, Bérubé R, Dumas P. , et al. Determination of bisphenol A, triclosan and their metabolites in human urine using isotope-dilution liquid chromatography-tandem mass spectrometry. J Chromatogr A 2014; 1348: 97-104
  • 49 Morisset AS, Weiler HA, Dubois L. , et al. Rankings of iron, vitamin D, and calcium intakes in relation to maternal characteristics of pregnant Canadian women. Appl Physiol Nutr Metab 2016; 41 (07) 749-757
  • 50 Arbuckle TE, Marro L, Davis K. , et al. Exposure to free and conjugated forms of bisphenol A and triclosan among pregnant women in the MIREC cohort. Environ Health Perspect 2015; 123 (04) 277-284
  • 51 Bae S, Kim JH, Lim YH, Park HY, Hong YC. Associations of bisphenol A exposure with heart rate variability and blood pressure. Hypertension 2012; 60 (03) 786-793
  • 52 Aekplakorn W, Chailurkit LO, Ongphiphadhanakul B. Association of serum bisphenol a with hypertension in thai population. Int J Hypertens 2015; 2015: 594189
  • 53 Shankar A, Teppala S. Urinary bisphenol A and hypertension in a multiethnic sample of US adults. J Environ Public Health 2012; 2012: 481641
  • 54 Levin KA. Study design III: cross-sectional studies. Evid Based Dent 2006; 7 (01) 24-25
  • 55 Song JW, Chung KC. Observational studies: cohort and case-control studies. Plast Reconstr Surg 2010; 126 (06) 2234-2242
  • 56 Dhingra R, Vasan RS. Age as a risk factor. Med Clin North Am 2012; 96 (01) 87-91
  • 57 Calafat AM, Koch HM, Swan SH. , et al. Misuse of blood serum to assess exposure to bisphenol A and phthalates. Breast Cancer Res 2013; 15 (05) 403
  • 58 Lakind JS, Levesque J, Dumas P, Bryan S, Clarke J, Naiman DQ. Comparing United States and Canadian population exposures from National Biomonitoring Surveys: bisphenol A intake as a case study. J Expo Sci Environ Epidemiol 2012; 22 (03) 219-226
  • 59 Stacy SL, Eliot M, Etzel T. , et al. Patterns, variability, and predictors of urinary triclosan concentrations during pregnancy and childhood. Environ Sci Technol 2017; 51 (11) 6404-6413
  • 60 Lassen TH, Frederiksen H, Kyhl HB. , et al. Prenatal triclosan exposure and anthropometric measures including anogenital distance in Danish infants. Environ Health Perspect 2016; 124 (08) 1261-1268
  • 61 WHO (World Health Organization). Toxicological and health aspects of bisphenol A. 2010. Available at: http://apps.who.int/iris/bitstream/10665/44624/1/97892141564274_eng.pdf . Accessed January 25, 2018
  • 62 Queckenberg C, Meins J, Wachall B. , et al. Absorption, pharmacokinetics, and safety of triclosan after dermal administration. Antimicrob Agents Chemother 2010; 54 (01) 570-572
  • 63 Weiss L, Arbuckle TE, Fisher M. , et al. Temporal variability and sources of triclosan exposure in pregnancy. Int J Hyg Environ Health 2015; 218 (06) 507-513
  • 64 Bertelsen RJ, Engel SM, Jusko TA. , et al. Reliability of triclosan measures in repeated urine samples from Norwegian pregnant women. J Expo Sci Environ Epidemiol 2014; 24 (05) 517-521
  • 65 Fisher M, Arbuckle TE, Mallick R. , et al. Bisphenol A and phthalate metabolite urinary concentrations: daily and across pregnancy variability. J Expo Sci Environ Epidemiol 2015; 25 (03) 231-239